A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form
A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 175 participants.
Also called NCT06540352
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 175 participants
- Registry
-
NCT06540352
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Russia
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06540352. Randomized; quadruple masking; primary purpose treatment. Start 2024-06-03 (actual); primary completion 2026-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term Use to Prevent Recurrence of Atrial Fibrillation/Flutter After Terminating Its Persistent Form
- Condition
- Atrial Fibrillation
- Condition
- Atrial Flutter
- Intervention (Drug)
- 4-Nitro-N-[(1RS)-1-(4-fluorophenyl)-2-(1-ethylpiperidin-4-yl)ethyl]benzamide hydrochloride
- Intervention (Drug)
- Mannitol
- Lead sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Record details
- Record id
cardio:ct-nct06540352- Content hash
9d6316978836e5a68718a9184ab2028ccfcd95ce5d35df3840ced5fe889e2ddc